Phase lb study of buparlisib (BKM120) plus either paclitaxel (PTX) in advanced solid tumors (aST) or PTX plus trastuzumab (TZ) in HER2+ breast cancer (BC)

627^ Background: Preclinical data show PI3K-pathway inhibition can enhance the efficacy of anticancer therapy, such as PTX or TZ. In this 4-arm Ph Ib study (NCT01285466), buparlisib (pan-PI3K inhib...